{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:47:49Z","timestamp":1792108069570,"version":"4.4.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["CI-IPOPGEBC_PTDC\/EME-APL\/1342\/2020"],"award-info":[{"award-number":["CI-IPOPGEBC_PTDC\/EME-APL\/1342\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/143717\/2019"],"award-info":[{"award-number":["SFRH\/BD\/143717\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011776","name":"Instituto Portugu\u00eas de Oncologia do Porto","doi-asserted-by":"publisher","award":["PI27-FB-GEBC_CI-IPOP-2016"],"award-info":[{"award-number":["PI27-FB-GEBC_CI-IPOP-2016"]}],"id":[{"id":"10.13039\/501100011776","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011776","name":"Instituto Portugu\u00eas de Oncologia do Porto","doi-asserted-by":"publisher","award":["SuHRBlaC-PI-191-CI-IPOP247020"],"award-info":[{"award-number":["SuHRBlaC-PI-191-CI-IPOP247020"]}],"id":[{"id":"10.13039\/501100011776","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.euf.2024.05.024","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T03:32:13Z","timestamp":1718767933000},"page":"922-934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Diagnostic Test Accuracy of Urinary DNA Methylation-based Biomarkers for the Detection of Primary and Recurrent Bladder Cancer: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5896-051X","authenticated-orcid":false,"given":"Mariana","family":"Silva-Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o A.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Salta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa S.","family":"Henriques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Pereira Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Monteiro-Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2024.05.024_b0005","unstructured":"Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: cancer today. International Agency for Research on Cancer; 2024. https:\/\/gco.iarc.who.int\/today."},{"key":"10.1016\/j.euf.2024.05.024_b0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.05.024_b0015","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1038\/551S34a","article-title":"Unlocking bladder cancer","volume":"551","author":"Berdik","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.euf.2024.05.024_b0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13148-022-01240-8","article-title":"Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation","volume":"14","author":"Hentschel","year":"2022","journal-title":"Clinic Epigenet"},{"key":"10.1016\/j.euf.2024.05.024_b0025","doi-asserted-by":"crossref","first-page":"66.e25","DOI":"10.1016\/j.urolonc.2014.06.008","article-title":"Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer","volume":"33","author":"Yafi","year":"2015","journal-title":"Urol Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.euf.2024.05.024_b0030","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1038\/modpathol.2008.193","article-title":"Diagnosis of urothelial carcinoma from urine","volume":"22","author":"T\u00eatu","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.euf.2024.05.024_b0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.21037\/tau.2018.09.11","article-title":"Epidemiology, aetiology and screening of bladder cancer","volume":"8","author":"Cumberbatch","year":"2019","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euf.2024.05.024_b0040","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.juro.2016.12.010","article-title":"Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study","volume":"197","author":"Kavalieris","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.05.024_b0045","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eururo.2019.04.035","article-title":"Evaluation of Cxbladder and adjudication of atypical cytology and equivocal cystoscopy","volume":"76","author":"Konety","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.05.024_b0050","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/bju.15194","article-title":"Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study","volume":"127","author":"Gontero","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2024.05.024_b0055","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.euf.2022.02.006","article-title":"Reducing the frequency of follow-up cystoscopy in low-grade pTa non-muscle-invasive bladder cancer using the ADXBLADDER biomarker","volume":"8","author":"Roupr\u00eat","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2024.05.024_b0060","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1007\/s00345-021-03629-1","article-title":"Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up","volume":"39","author":"Cancel-Tassin","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2024.05.024_b0065","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3390\/cancers14030618","article-title":"The role of new technologies in the diagnosis and surveillance of non-muscle-invasive bladder carcinoma: a prospective, double-blinded, monocentric study of the XPERT\u00a9 Bladder Cancer Monitor and Narrow Band Imaging\u00a9 cystoscopy","volume":"14","author":"Singer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euf.2024.05.024_b0070","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bju.14673","article-title":"Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle invasive bladder cancer","volume":"123","author":"D'Andrea","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2024.05.024_b0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.euo.2018.06.011","article-title":"Performance of the bladder EpiCheck\u2122 methylation test for patients under surveillance for non-muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial","volume":"1","author":"Witjes","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2024.05.024_b0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/diagnostics10010039","article-title":"Biomarkers for bladder cancer diagnosis and surveillance: a comprehensive review","volume":"10","author":"Batista","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.euf.2024.05.024_b0085","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2147\/OTT.S283891","article-title":"The development of non-invasive diagnostic tools in bladder cancer","volume":"15","author":"Schulz","year":"2022","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.euf.2024.05.024_b0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41576-018-0074-2","article-title":"Clinical epigenetics: seizing opportunities for translation","volume":"20","author":"Berdasco","year":"2019","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.euf.2024.05.024_b0095","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/10408363.2017.1410520","article-title":"Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory","volume":"54","author":"Garc\u00eda-Gim\u00e9nez","year":"2017","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.euf.2024.05.024_b0100","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1158\/1078-0432.CCR-10-1312","article-title":"Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples","volume":"16","author":"Costa","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2024.05.024_b0105","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/1354750X.2014.889211","article-title":"Evaluation of diagnostic accuracy of DNA methylation biomarkers for bladder cancer: a systematic review and meta-analysis","volume":"19","author":"Chen","year":"2014","journal-title":"Biomarkers"},{"key":"10.1016\/j.euf.2024.05.024_b0110","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/epi-2017-0156","article-title":"The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review","volume":"10","author":"Bosschieter","year":"2018","journal-title":"Epigenomics"},{"key":"10.1016\/j.euf.2024.05.024_b0115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.euf.2024.05.024_b0120","article-title":"Meta-analysis of diagnostic accuracy with mada","author":"Doebler","year":"2015","journal-title":"R Packages"},{"key":"10.1016\/j.euf.2024.05.024_b0125","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0895-4356(03)00177-X","article-title":"The diagnostic odds ratio: a single indicator of test performance","volume":"56","author":"Glas","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euf.2024.05.024_b0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13148-016-0303-5","article-title":"UroMark\u2014a urinary biomarker assay for the detection of bladder cancer","volume":"9","author":"Feber","year":"2017","journal-title":"Clinic Epigenet"},{"key":"10.1016\/j.euf.2024.05.024_b0135","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.1172\/JCI139597","article-title":"Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.euf.2024.05.024_b0140","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13148-021-01029-1","article-title":"Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples","volume":"13","author":"Piatti","year":"2021","journal-title":"Clin Epigenet"},{"key":"10.1016\/j.euf.2024.05.024_b0145","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1186\/s12885-022-09616-y","article-title":"A novel and sensitive DNA methylation marker for the urine-based liquid biopsies to detect bladder cancer","volume":"22","author":"Deng","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euf.2024.05.024_b0150","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13148-022-01335-2","article-title":"BladMetrix: a novel urine DNA methylation test with high accuracy for detection of bladder cancer in hematuria patients","volume":"14","author":"Pharo","year":"2022","journal-title":"Clinic Epigenet"},{"key":"10.1016\/j.euf.2024.05.024_b0155","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/1471-2407-13-275","article-title":"Diagnostic markers of urothelial cancer based on DNA methylation analysis","volume":"13","author":"Chihara","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euf.2024.05.024_b0160","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1186\/s12885-017-3758-7","article-title":"DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells","volume":"17","author":"Tan","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euf.2024.05.024_b0165","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.urolonc.2009.01.003","article-title":"Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: a prospective, two-center validation study","volume":"29","author":"Vinci","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2024.05.024_b0170","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ijc.10971","article-title":"Frequent hypermethylation of promoter region of RASSF1A in tumour tissues and voided urine of urinary bladder cancer patients","volume":"104","author":"Chan","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euf.2024.05.024_b0175","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.18632\/oncotarget.6666","article-title":"An epigenetic biomarker combination of PCDH17 and POU4F2 detects bladder cancer accurately by methylation analyses of urine sediment DNA in Han Chinese","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2024.05.024_b0180","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12885-022-09268-y","article-title":"Improved urine DNA methylation panel for early bladder cancer detection","volume":"22","author":"Fang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euf.2024.05.024_b0185","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012799","article-title":"STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration","volume":"6","author":"Cohen","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.euf.2024.05.024_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-1827.2009.02477.x","article-title":"Non-invasive papillary urothelial neoplasms: the 2004 WHO\/ISUP classification system","volume":"60","author":"Miyamoto","year":"2010","journal-title":"Pathol Int"},{"key":"10.1016\/j.euf.2024.05.024_b0195","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2014part B: prostate and urinary tract tumours","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.05.024_b0200","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/dc.24561","article-title":"The Paris system of reporting urinary cytology: strengths and opportunities","volume":"48","author":"Kurtycz","year":"2020","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.euf.2024.05.024_b0205","first-page":"464","article-title":"Hypermethylation of multiple genes in tumour tissues and voided urine in urinary bladder cancer patients","volume":"8","author":"Chan","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2024.05.024_b0210","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1158\/1078-0432.CCR-04-0930","article-title":"Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients","volume":"10","author":"Friedrich","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"7 Pt 1","key":"10.1016\/j.euf.2024.05.024_b0215","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1158\/1078-0432.CCR-05-2468","article-title":"Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection","volume":"12","author":"Urakami","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2024.05.024_b0220","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1038\/sj.onc.1209209","article-title":"Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls","volume":"25","author":"Yates","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.euf.2024.05.024_b0225","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1158\/1078-0432.CCR-07-0861","article-title":"A novel set of DNA methylation markers in urine sediments for sensitive\/specific detection of bladder cancer","volume":"13","author":"Yu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2024.05.024_b0230","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/path.2390","article-title":"Discovery of myopodin methylation in bladder cancer","volume":"216","author":"Cebrian","year":"2008","journal-title":"J Pathol"},{"key":"10.1016\/j.euf.2024.05.024_b0235","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/j.1464-410X.2008.07591.x","article-title":"A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis","volume":"101","author":"Roupr\u00eat","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2024.05.024_b0240","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00432-009-0619-z","article-title":"Hypermethylated SFRP1, but none of other nine genes \u201cinformative\u201d for western countries, is valuable for bladder cancer detection in mainland China","volume":"135","author":"Sun","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.euf.2024.05.024_b0245","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.urolonc.2008.12.008","article-title":"Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine","volume":"28","author":"Lin","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2024.05.024_b0250","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2009.07.041","article-title":"Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples","volume":"58","author":"Renard","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.05.024_b0255","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jmoldx.2010.11.008","article-title":"Multiplexed methylation profiles of tumour suppressor genes in bladder cancer","volume":"13","author":"Cabello","year":"2011","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.euf.2024.05.024_b0260","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1755-8794-4-45","article-title":"Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine","volume":"4","author":"Chen","year":"2011","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.euf.2024.05.024_b0265","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.4161\/epi.6.9.16376","article-title":"TCF21 and PCDH17 methylation: an innovative panel of biomarkers for a simultaneous detection of urological cancers","volume":"6","author":"Costa","year":"2011","journal-title":"Epigenetics"},{"key":"10.1016\/j.euf.2024.05.024_b0270","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1158\/1078-0432.CCR-10-2659","article-title":"Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumour markers","volume":"17","author":"Reinert","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2024.05.024_b0275","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ijc.25651","article-title":"Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events","volume":"129","author":"Serizawa","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euf.2024.05.024_b0280","unstructured":"Berrada N, Amzazi S, Ameziane El Hassani R, et al. Epigenetic alterations of adenomatous polyposis coli (APC), retinoic acid receptor beta (RAR\u03b2) and survivin genes in tumour tissues and voided urine of bladder cancer patients. Cell Mol Biol (Noisy-le-grand) 2012;Suppl.58:Ol1744\u201351."},{"key":"10.1016\/j.euf.2024.05.024_b0285","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.clinbiochem.2012.01.010","article-title":"Urinary retinoic acid receptor-\u03b22 gene promoter methylation and hyaluronidase activity as noninvasive tests for diagnosis of bladder cancer","volume":"45","author":"Eissa","year":"2012","journal-title":"Clin Biochem"},{"key":"10.1016\/j.euf.2024.05.024_b0290","first-page":"17","article-title":"A noninvasive multi-analyte diagnostic assay: combining protein and DNA markers to stratify bladder cancer patients","volume":"4","author":"Fernandez","year":"2012","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.euf.2024.05.024_b0295","doi-asserted-by":"crossref","first-page":"e46297","DOI":"10.1371\/journal.pone.0046297","article-title":"Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation","volume":"7","author":"Reinert","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2024.05.024_b0300","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.juro.2012.08.015","article-title":"Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer","volume":"188","author":"Scher","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.05.024_b0305","doi-asserted-by":"crossref","first-page":"e35175","DOI":"10.1371\/journal.pone.0035175","article-title":"Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population","volume":"7","author":"Zhao","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2024.05.024_b0310","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1464-410X.2011.10428.x","article-title":"A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine","volume":"109","author":"Zuiverloon","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2024.05.024_b0315","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.juro.2013.01.105","article-title":"Methylation of a novel panel of tumour suppressor genes in urine moves forward noninvasive diagnosis and prognosis of bladder cancer: a 2-center prospective study","volume":"190","author":"Garc\u00eda-Baquero","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.05.024_b0320","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-12-3276","article-title":"A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine","volume":"19","author":"Kandimalla","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2024.05.024_b0325","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.eururo.2012.11.030","article-title":"Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer","volume":"63","author":"Shimizu","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.05.024_b0330","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1089\/dna.2013.2030","article-title":"Hypermethylation of TWIST1 and NID2 in tumour tissues and voided urine in urinary bladder cancer patients","volume":"32","author":"Yegin","year":"2013","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.euf.2024.05.024_b0335","doi-asserted-by":"crossref","first-page":"51.e21","DOI":"10.1016\/j.urolonc.2013.08.003","article-title":"Clinical performance and utility of a DNA methylation urine test for bladder cancer","volume":"32","author":"Abern","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2024.05.024_b0340","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.18632\/oncotarget.1949","article-title":"Epigenetic inactivation of VGF associated with urothelial cell carcinoma and its potential as a non-invasive biomarker using urine","volume":"5","author":"Hayashi","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2024.05.024_b0345","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.18632\/oncotarget.2129","article-title":"An epigenetic marker panel for recurrence risk prediction of low-grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine","volume":"5","author":"Maldonado","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2024.05.024_b0350","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1158\/1078-0432.CCR-13-2637","article-title":"A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence","volume":"20","author":"Su","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2024.05.024_b0355","doi-asserted-by":"crossref","first-page":"29555","DOI":"10.18632\/oncotarget.4986","article-title":"Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumour suppressor and a potential non\u2013invasive biomarker for the detection of urothelial carcinoma","volume":"6","author":"Yeh","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2024.05.024_b0360","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.eururo.2016.06.035","article-title":"A prospective blinded evaluation of urine-DNA testing for detection of urothelial bladder carcinoma in patients with gross hematuria","volume":"70","author":"Dahmcke","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.05.024_b0365","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1186\/s12885-016-2748-5","article-title":"Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive\/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non\u2013muscle-invasive bladder cancer","volume":"16","author":"Roperch","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euf.2024.05.024_b0370","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.juro.2015.08.085","article-title":"Evaluation of an epigenetic profile for the detection of bladder cancer in patients with hematuria","volume":"195","author":"van Kessel","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.05.024_b0375","doi-asserted-by":"crossref","first-page":"327","DOI":"10.7754\/Clin.Lab.2015.150602","article-title":"Improved noninvasive bladder cancer diagnosis using urine sediments and novel DNA methylation biomarker panels","volume":"62","author":"Wang","year":"2016","journal-title":"Clin Lab"},{"key":"10.1016\/j.euf.2024.05.024_b0380","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3233\/CBM-160261","article-title":"Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer","volume":"18","author":"Fantony","year":"2017","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.euf.2024.05.024_b0385","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/CBM-160673","article-title":"Detection of bladder cancer in urine sediments by a hypermethylation panel of selected tumour suppressor genes","volume":"18","author":"Pietrusi\u0144ski","year":"2017","journal-title":"Cancer Biomark"},{"issue":"3 Pt 1","key":"10.1016\/j.euf.2024.05.024_b0390","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.juro.2016.09.118","article-title":"Validation of a DNA methylation-mutation urine assay to select patients with hematuria for cystoscopy","volume":"197","author":"van Kessel","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.05.024_b0395","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.urology.2017.11.025","article-title":"Evaluation of urinary DNA methylation as a marker for recurrent bladder cancer: a 2-center prospective study","volume":"113","author":"Shindo","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.euf.2024.05.024_b0400","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13148-018-0496-x","article-title":"Urine cell\u2013based DNA methylation classifier for monitoring bladder cancer","volume":"10","author":"Van Der Heijden","year":"2018","journal-title":"Clinic Epigenet"},{"key":"10.1016\/j.euf.2024.05.024_b0405","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2217\/epi-2018-0094","article-title":"A two-gene methylation signature for the diagnosis of bladder cancer in urine","volume":"11","author":"Bosschieter","year":"2019","journal-title":"Epigenomics"},{"key":"10.1016\/j.euf.2024.05.024_b0410","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/cncy.22152","article-title":"Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle invasive bladder cancer","volume":"127","author":"Trenti","year":"2019","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.euf.2024.05.024_b0415","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3390\/cancers12040859","article-title":"Comparative analysis of urine fractions for optimal bladder cancer detection using DNA methylation markers","volume":"12","author":"Hentschel","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.euf.2024.05.024_b0420","doi-asserted-by":"crossref","first-page":"603.e1","DOI":"10.1016\/j.urolonc.2020.01.007","article-title":"A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade","volume":"38","author":"Hermanns","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2024.05.024_b0425","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3390\/jcm9020605","article-title":"A multiplex test assessing MiR663ame and VIMme in urine accurately discriminates bladder cancer from inflammatory conditions","volume":"9","author":"Monteiro-Reis","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.euf.2024.05.024_b0430","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3390\/ijms21031117","article-title":"ITIH5 and ECRG4 DNA methylation biomarker test (EI-BLA) for urine-based non-invasive detection of bladder cancer","volume":"21","author":"Rose","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euf.2024.05.024_b0435","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clgc.2019.10.007","article-title":"High detection rate for non-muscle-invasive bladder cancer using an approved DNA methylation signature test","volume":"18","author":"Steinbach","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euf.2024.05.024_b0440","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.euf.2018.09.016","article-title":"HOXA9, PCDH17, POU4F2, and ONECUT2 as a urinary biomarker combination for the detection of bladder cancer in Chinese patients with hematuria","volume":"6","author":"Wu","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2024.05.024_b0445","first-page":"214","article-title":"DNA hypermethylation of a panel of genes as an urinary biomarker for bladder cancer diagnosis","volume":"19","author":"Georgopoulos","year":"2021","journal-title":"Urol J"},{"key":"10.1016\/j.euf.2024.05.024_b0450","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13148-021-01073-x","article-title":"A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer","volume":"13","author":"Ruan","year":"2021","journal-title":"Clinic Epigenet"},{"key":"10.1016\/j.euf.2024.05.024_b0455","doi-asserted-by":"crossref","first-page":"105.e11","DOI":"10.1016\/j.urolonc.2021.11.001","article-title":"Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: a single centre, prospective, blinded clinical trial","volume":"40","author":"Cochetti","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2024.05.024_b0460","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1186\/s12885-022-10275-2","article-title":"Identification and validation of methylated PENK gene for early detection of bladder cancer using urine DNA","volume":"22","author":"Oh","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euf.2024.05.024_b0465","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.3390\/jcm11133855","article-title":"Usefulness of the urine methylation test (Bladder EpiCheck\u00ae) in follow-up patients with non-muscle invasive bladder cancer and cytological diagnosis of atypical urothelial cells\u2014an institutional study","volume":"11","author":"Pe\u00f1a","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.euf.2024.05.024_b0470","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/j.clgc.2022.03.009","article-title":"The role of Bladder Epicheck test in follow-up of patients with non-muscle invasive bladder cancer","volume":"20","author":"Ragonese","year":"2022","journal-title":"Clin Genitourin Cancer"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924000889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924000889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T20:26:35Z","timestamp":1747081595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456924000889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2405456924000889"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2024.05.024","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic Test Accuracy of Urinary DNA Methylation-based Biomarkers for the Detection of Primary and Recurrent Bladder Cancer: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2024.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}